statement
SIM0725 is a long-acting antagonistic monoclonal antibody targeting the interleukin-2 receptor beta chain (CD122).
A statement by 先聲藥業集團. Statements are as reported by the cited publishers — not verified by DecisionGateway.
靶向白細胞介素-2受體β鏈（CD122）長效拮抗型單克隆抗體SIM0725
Discussion
Related claims
SIM0725 has been approved by the National Medical Products Administration to conduct clinical trials in China.先聲藥業集團 · investigationSIM0725 is intended for the treatment of autoimmune diseases.先聲藥業集團 · statementSIM0725 was independently developed by the company.先聲藥業集團 · statementIMVT-1402 is designed so its binding epitope does not compete with albumin, allowing high-dose continuous administration without hypercholesterolemia concerns, whereas Batoclimab requires dose reduction after several weeks.하나증권 제약/바이오 김선아 · statementCagriSema consists of the long-acting amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.界面新闻 · statementIMVT-1402 in refractory rheumatoid arthritis achieved statistical significance in the Period 2 ACR20 response rate, with the 600mg group meeting key endpoints at week 28 on both ACR20 and ACR50 versus placebo.현대차증권 제약/바이오/의료기기 김현석 · statement
More claims by 先聲藥業集團
SIM0725 was independently developed by the company.statementSIM0725 is intended for the treatment of autoimmune diseases.statementSIM0725 has been approved by the National Medical Products Administration to conduct clinical trials in China.investigation
All claims by 先聲藥業集團